Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Estybon (rigosertib)
i
Other names:
ON01910, ON01910.Na, ON 01910, ON 01910.Na, ON-01910, ON-01910.Na, SyB L-1101, SyB C-1101
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(7)
News
Trials
Company:
Knight Therap, Pint Pharma, Specialised Therap, SymBio Pharma, Traws Pharma
Drug class:
PI3K inhibitor, PLK1 inhibitor, RAS antagonist
Related drugs:
‹
RTB101 (43)
PF-05212384 (31)
RG7440 (27)
chidamide (23)
GDC-0941 (22)
AN2025 (20)
GSK2126458 (17)
MEN1611 (16)
CUDC-907 (8)
LY294002 (7)
PF-04691502 (6)
RP6530 (6)
LY3023414 (5)
GDC-0980 (4)
A66 (3)
enzastaurin (3)
GDC-0084 (3)
PI-103 (2)
AEZS 136 (1)
AEZS-129 (1)
AZD8835 (1)
BAY 1082439 (1)
CB-006-3 (1)
DFN-529 (1)
KU-0060648 (1)
OP-11 (1)
SB02024 (1)
SRX3262 (1)
SAR245408 (1)
CBL0102 (1)
ASN003 (0)
AUM302 (0)
BGT226 (0)
DS-7423 (0)
ETP-47187 (0)
GDC-0349 (0)
GSK1059615 (0)
HEC68498 (0)
IBL-202 (0)
IBL-301 (0)
MTX-211 (0)
PIK-75 (0)
SAR260301 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SL-901 (0)
SRX3177 (0)
TG 100-115 (0)
TOP216 (0)
VCD-597 (0)
VS-5584 (0)
WYE-125132 (0)
PQR309 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
VT-11CR (0)
PX 866 (0)
SAR245409 (0)
NBL-001 (18)
PCM-075 (12)
BI2536 (3)
BAL0891 (0)
GSK461364 (0)
HMN-176 (0)
HMN-214 (0)
KD 032 (0)
RTB101 (43)
PF-05212384 (31)
RG7440 (27)
chidamide (23)
GDC-0941 (22)
AN2025 (20)
GSK2126458 (17)
MEN1611 (16)
CUDC-907 (8)
LY294002 (7)
PF-04691502 (6)
RP6530 (6)
LY3023414 (5)
GDC-0980 (4)
A66 (3)
enzastaurin (3)
GDC-0084 (3)
PI-103 (2)
AEZS 136 (1)
AEZS-129 (1)
AZD8835 (1)
BAY 1082439 (1)
CB-006-3 (1)
DFN-529 (1)
KU-0060648 (1)
OP-11 (1)
SB02024 (1)
SRX3262 (1)
SAR245408 (1)
CBL0102 (1)
ASN003 (0)
AUM302 (0)
BGT226 (0)
DS-7423 (0)
ETP-47187 (0)
GDC-0349 (0)
GSK1059615 (0)
HEC68498 (0)
IBL-202 (0)
IBL-301 (0)
MTX-211 (0)
PIK-75 (0)
SAR260301 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SL-901 (0)
SRX3177 (0)
TG 100-115 (0)
TOP216 (0)
VCD-597 (0)
VS-5584 (0)
WYE-125132 (0)
PQR309 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
VT-11CR (0)
PX 866 (0)
SAR245409 (0)
NBL-001 (18)
PCM-075 (12)
BI2536 (3)
BAL0891 (0)
GSK461364 (0)
HMN-176 (0)
HMN-214 (0)
KD 032 (0)
›
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive: C2 – Inclusion Criteria
nivolumab + rigosertib
Sensitive
:
C2
nivolumab + rigosertib
Sensitive: C2 – Inclusion Criteria
nivolumab + rigosertib
Sensitive
:
C2
KRAS G12D
Non Small Cell Lung Cancer
KRAS G12D
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive: C3 – Early Trials
nivolumab + rigosertib
Sensitive
:
C3
nivolumab + rigosertib
Sensitive: C3 – Early Trials
nivolumab + rigosertib
Sensitive
:
C3
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive: C3 – Early Trials
nivolumab + rigosertib
Sensitive
:
C3
nivolumab + rigosertib
Sensitive: C3 – Early Trials
nivolumab + rigosertib
Sensitive
:
C3
KRAS G12V
Non Small Cell Lung Cancer
KRAS G12V
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive: C3 – Early Trials
nivolumab + rigosertib
Sensitive
:
C3
nivolumab + rigosertib
Sensitive: C3 – Early Trials
nivolumab + rigosertib
Sensitive
:
C3
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
rigosertib
Sensitive: D – Preclinical
rigosertib
Sensitive
:
D
rigosertib
Sensitive: D – Preclinical
rigosertib
Sensitive
:
D
NRAS mutation
Colorectal Cancer
NRAS mutation
Colorectal Cancer
rigosertib
Sensitive: D – Preclinical
rigosertib
Sensitive
:
D
rigosertib
Sensitive: D – Preclinical
rigosertib
Sensitive
:
D
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
rigosertib
Sensitive: D – Preclinical
rigosertib
Sensitive
:
D
rigosertib
Sensitive: D – Preclinical
rigosertib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login